Gene · 1584
CYP11B1: cytochrome P450 family 11 subfamily B member 1
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. CYP11B1: cytochrome P450 family 11 subfamily B member 1. Genes, record 1584. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/1584
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| P15538 | Cytochrome P450 11B1, mitochondrial | 503 | 2 | Ensembl, GeneID, HGNC |
Source UniProt
Patents17
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| JP 2026004568 A | 2026-01-14 | 42838 | P15538 | Espacenet |
| EP 4641201 A2 | 2025-10-29 | 3084 | P15538 | Espacenet |
| JP 2025517969 A | 2025-06-12 | 3084 | P15538 | Espacenet |
| US 11446398 B2 | 2022-09-20 | 21896 | P15538 | Espacenet |
| JP 2022524081 A | 2022-04-27 | 124867 | P15538 | Espacenet |
| US 11078247 B2 | 2021-08-03 | 2798 | P15538 | Espacenet |
| JP 2019054813 A | 2019-04-11 | 223273 | P15538 | Espacenet |
| JP 2017121241 A | 2017-07-13 | 223273 | P15538 | Espacenet |
| WO 2016164476 A2 | 2016-10-13 | 2 | P15538 | Espacenet |
| WO 2015111155 A | 2015-07-30 | 68 | P15538 | Espacenet |
1 to 10 of 17
See all 17 patentsDrugs5
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
| Drug | ChEMBL ID | Mechanism | Action | Source |
|---|---|---|---|---|
| LEVOKETOCONAZOLE | CHEMBL295698 | Cytochrome P450 11B1 inhibitor | INHIBITOR | ChEMBL |
| METYRAPONE | CHEMBL934 | Cytochrome P450 11B1, mitochondrial inhibitor | INHIBITOR | ChEMBL |
| MITOTANE | CHEMBL1670 | Cytochrome P450 11B1 inhibitor | INHIBITOR | ChEMBL |
| OSILODROSTAT | CHEMBL3099695 | Cytochrome P450 11B1 inhibitor | INHIBITOR | ChEMBL |
| OSILODROSTAT PHOSPHATE | CHEMBL3707393 | Cytochrome P450 11B1 inhibitor | INHIBITOR | ChEMBL |
Trials42
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
| Trial | Drug | Phase | Results first posted | Source |
|---|---|---|---|---|
| NCT06831175 | MITOTANE | PHASE2 | ClinicalTrials.gov | |
| NCT06556277 | METYRAPONE | ClinicalTrials.gov | ||
| NCT06430528 | OSILODROSTAT | ClinicalTrials.gov | ||
| NCT05913427 | MITOTANE | PHASE2 | ClinicalTrials.gov | |
| NCT05634577 | MITOTANE | PHASE2 | 2025-06-19 | ClinicalTrials.gov |
| NCT05633953 | OSILODROSTAT | 2025-02-10 | ClinicalTrials.gov | |
| NCT05382156 | OSILODROSTAT | ClinicalTrials.gov | ||
| NCT05344027 | MITOTANE | ClinicalTrials.gov | ||
| NCT05255900 | METYRAPONE | ClinicalTrials.gov | ||
| NCT04933916 | METYRAPONE | PHASE1/PHASE2 | ClinicalTrials.gov |
1 to 10 of 42
See all 42 trialsNIH grants869
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | CYP11B1 papers | Newest fiscal year |
|---|---|---|---|
| R01DK043140 | Mechanisms Leading to Adrenal Zonation | 32 | 2025 |
| U54GM115428 | Mississippi Center for Clinical and Translational Research | 20 | 2025 |
| R01GM086596 | Activation of androgen biosynthesis and drug metabolism by cytochrome b5 | 19 | 2025 |
| R01DK062027 | Mechanisms of Adrenal Differentiation | 8 | 2025 |
| P30DK020572 | Michigan Diabetes Research Center (MDRC) | 6 | 2025 |
| P30CA046592 | University of Michigan Rogel Cancer Center Support Grant 2023-2028 | 5 | 2025 |
| P50CA097186 | The Pacific Northwest Prostate Cancer SPORE | 5 | 2025 |
| R35GM133375 | Structural regulation of Class-I and Class-II cytochrome P450 enzymes | 4 | 2025 |
| P30CA016056 | Roswell Park Cancer Center Support Grant | 3 | 2025 |
| P30CA016672 | Cancer Center Support Grant | 3 | 2025 |
1 to 10 of 869Source NIH's project files
See all 869 nih grantsPapers2,770
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Aldosterone Synthase Inhibitors: Emerging Therapeutic Strategies in Resistant Hypertension. | Life (Basel) | 2026 | 42795360 | PubTator, text mining | PubMed |
| Identification of a novel small-molecule compound that suppresses depolarization-induced CYP11B2 expression and aldosterone production in KCNJ5 mutant adrenocortical cells. | Biochem Biophys Res Commun | 2026 | 42777615 | PubTator, text mining | PubMed |
| 18F-CETO in adrenocortical carcinoma: first clinical-translational study of an adrenocortical-targeting PET tracer. | Endocr Relat Cancer | 2026 | 42775908 | PubTator, text mining | PubMed |
| Persistent Müllerian structures in an infant with complete androgen insensitivity syndrome. | JCEM Case Rep | 2026 | 42756908 | PubTator, text mining | PubMed |
| [Clinical analysis of two cases of 11β-hydroxylase deficiency diagnosed after adrenal mass resection]. | Zhonghua Nei Ke Za Zhi | 2026 | 42733267 | PubTator, text mining | PubMed |
| Incidental discovery of neglected 11β-hydroxylase deficiency causing 46,XX disorder of sex development in a 35-year-old adult: A radiologically driven diagnosis. | Radiol Case Rep | 2026 | 42707067 | PubTator, text mining | PubMed |
| APUC-6 Genes as a Potential Prognostic and Predictive Biomarker in the CHAARTED Prostate Cancer Trial. | JCO Precis Oncol | 2026 | 42628007 | PubTator, text mining | PubMed |
| Bilateral adrenal adenomas presenting with ACTH-independent Cushing's syndrome and primary aldosteronism: diagnostic insights from multi-steroid adrenal venous sampling. | Front Endocrinol (Lausanne) | 2026 | 42609288 | PubTator, text mining | PubMed |
| [A follow-up study of 10 Uyghur children with 11β-hydroxylase deficiency in the Xinjiang region]. | Zhongguo Dang Dai Er Ke Za Zhi | 2026 | 42608305 | PubTator, text mining | PubMed |
| Clinical and genetic characteristics of patients with complete androgen insensitivity syndrome: an experience from a tertiary care centre of Kashmir Valley. | Endocrine | 2026 | 42545618 | PubTator, text mining | PubMed |
1 to 10 of 2,770
See all 2,770 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/1584
GET https://conductscience.org/api/genes/v1/1584/patents